| Ytd | 18.45% | |
| 1y | 2.00% |
| Open | 52.72 | Prev Close | 53.05 | Low | 48.74 | High | 53.49 | Mkt Cap | 4.70B |
| Vol | 686.88K | Avg Vol | 833.21K | EPS | -1.29 | P/E | N/A | Forward P/E | 13.75 |
| Beta | 1.02 | Short Ratio | 4.25 | Inst. Own | 105.72% | Dividend | 1.62 | Div Yield | 3.05 |
| Ex Div Date | 09-04 | Earning | 11-02 | 50-d Avg | 53.21 | 200-d Avg | 56.41 | 1yr Est | 76.50 |
LONG BEACH, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) p
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE
Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement wit
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and b
California Resources (NYSE: CRC - Get Free Report) and Kinetik (NYSE: KNTK - Get Free Report) are bo
Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target t
CRC plans to sell its non-core Uinta Basin assets for about $90 million, freeing cash to support its
Stephens & Co. analyst Mike Scialla maintains California Resources (NYSE:CRC) with a Overweig
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Europea
Roth Capital analyst Leo Mariani maintains California Resources (NYSE:CRC) with a Buy and raises
LONG BEACH, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC)
RBC Capital analyst Scott Hanold reiterates California Resources (NYSE:CRC) with a Outperform and
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/ur
California Resources (CRC) reported earnings 30 days ago. What's next for the stock?
CRC's $63 million Crimson acquisition expands its California pipeline network, boosting transport fl
LONG BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC)
LONG BEACH, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) t
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results
California Resources is cutting costs and improving drilling efficiency, but weaker estimates and ma
California Resources Corporation is cutting costs and improving well productivity, but a rich valuat
California Resources Corporation is adding pipelines, storage and market access after Q2 bottlenecks
Barclays analyst Betty Jiang maintains California Resources (NYSE:CRC) with a Overweight and lowe
CRC's revenues surge 50.4% as Berry synergies, drilling gains and midstream expansion support growth
Bank of America Corp DE lifted its holdings in shares of California Resources Corporation (NYSE: CRC
UBS analyst Josh Silverstein maintains California Resources (NYSE:CRC) with a Buy and lowers the
Barclays analyst Betty Jiang maintains California Resources (NYSE:CRC) with a Overweight and lowe
California Resources (NYSE:CRC) reported quarterly earnings of $0.99 per share which missed the anal
Stephens & Co. analyst Mike Scialla maintains California Resources (NYSE:CRC) with a Overweig
UBS analyst Josh Silverstein maintains California Resources (NYSE:CRC) with a Buy and lowers the
Mizuho analyst Nitin Kumar maintains California Resources (NYSE:CRC) with a Outperform and raises
California Resources Corporation (NYSE:CRC) has achieved the first landmark carbon dioxide (CO2) inj
Citigroup analyst Scott Gruber upgrades California Resources (NYSE:CRC) from Neutral to Buy and r
UBS analyst Josh Silverstein maintains California Resources (NYSE:CRC) with a Buy and lowers the
California Resources (NYSE:CRC) reported quarterly earnings of $0.88 per share which beat the analys
JP Morgan maintains Neutral rating on California Resources Corp. with $63 price target. Company face
US. stock futures rose on Monday following Friday's advances. Futures of all fourth benchmark in
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly los
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1